New Startup Raises $106M to Treat Schizophrenia, Epilepsy

Millions of Americans living with brain disorders just got a major reason for hope.

Tortugas Neuroscience launched this week with $106 million in funding to develop four promising treatments for conditions ranging from schizophrenia to severe epilepsy. The Boston-based startup plans to bring these medicines to U.S. patients through mid-stage clinical trials.

The company is taking a smart approach by licensing drugs that have already shown promise overseas. Two treatments for schizophrenia and tinnitus come from Chinese pharmaceutical company Jiangsu Hansoh, while two others targeting focal epilepsy and encephalopathies originated from Japanese drugmaker Eisai.

This matters because developing brain disorder treatments from scratch takes decades and billions of dollars. By starting with medicines that have already cleared early safety hurdles, Tortugas could bring relief to patients years faster than traditional drug development.

The funding comes from three major venture capital firms: Cure Ventures, The Column Group, and AN Ventures. Their investment signals strong confidence that these treatments could actually work.

Tortugas was founded by veterans from Sage Therapeutics, including Jeff Jonas and Al Robichaud, who bring decades of neuroscience drug development experience. They know the challenges of treating brain disorders and the urgent need for better options.

The Ripple Effect

Nearly one in five American adults experiences mental illness each year, with schizophrenia affecting about 2.8 million people. Tinnitus impacts roughly 50 million Americans, while epilepsy affects 3.4 million people nationwide. Better treatments could transform millions of lives.

The startup also represents a shift in how American biotech views global partnerships. While Chinese biotech companies have gained attention for obesity drugs and cancer therapies, Tortugas shows they're also advancing neuroscience in meaningful ways.

For patients and families dealing with these challenging conditions, new treatment options can't come soon enough. Each successful drug means fewer people struggling without effective help.

The company expects to begin U.S. trials soon, bringing these international discoveries to American patients who need them.